TG Therapeutics (NASDAQ:TGTX) executives highlighted rapid revenue growth for BRIUMVI in 2025, expanding adoption in relapsing multiple sclerosis (RMS), and multiple upcoming clinical and regulatory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results